Last updated: December 28, 2025
Executive Summary
This report provides a comprehensive analysis of the litigation between Janssen Pharmaceuticals, Inc. (Plaintiff) and Mylan Laboratories Limited (Defendant) under case number 2:20-cv-13103. Filed in the United States District Court for the District of New Jersey, the case involves patent infringement allegations concerning a biosimilar drug product. The litigation exemplifies the strategic legal battles within the complex pharmaceutical patent landscape, specifically in biosimilar development and commercialization.
Key highlights:
- Nature of the dispute: Patent infringement relating to a biosimilar drug.
- Jurisdiction: U.S. District Court, District of New Jersey.
- Case filing date: December 15, 2020.
- Primary legal issue: Patent validity and infringement concerning Janssen’s patent rights on the reference biologic product.
- Current status: As of the latest update (Q1 2023), the case awaits trial preparation, with ongoing motions and discovery activities.
Background Context
Biosimilar Market Dynamics
Biosimilars are biologic medical products highly similar to already approved reference biologics. Since the U.S. enacted the Biosimilar Price Competition and Innovation Act (BPCIA) in 2010, patent disputes have proliferated as biosimilar manufacturers challenge patent exclusivities to accelerate market entry.
Parties Involved
| Party |
Role |
Key Details |
| Janssen Pharmaceuticals, Inc. |
Plaintiff |
Original biologic patent holder for Remicade (infliximab). |
| Mylan Laboratories Limited |
Defendant |
Biosimilar developer seeking regulatory approval for a biosimilar to infliximab. |
Reference Biologic and Patent
- Biologic: Remicade (infliximab)
- Patent involved: U.S. Patent No. 9,434,723, covering manufacturing processes and composition.
Case Timeline and Procedural History
| Date |
Event |
Details |
| Dec 15, 2020 |
Complaint filed |
Janssen files patent infringement suit against Mylan, alleging unauthorized biosimilar development. |
| Jan 2021 |
Service of process |
Mylan responds, asserting challenges to the patent's validity and non-infringement. |
| Q2 2021 |
Preliminary motions |
Motions to dismiss and claim constructions are filed and pending decision. |
| Q3 2021 – Q4 2022 |
Discovery phase |
Exchange of documents, depositions, and expert reports, focusing on patent scope and infringement. |
| Jan 2023 |
Summary judgment motions |
Parties file motions arguing for judgment based on patent validity and infringement. |
| Q2 2023 |
Trial scheduled |
Trial date set for August 2023, pending pre-trial motions and potential settlements. |
Legal Claims and Defenses
Janssen's Allegations
- Patent Infringement: Mylan's proposed biosimilar product infringes claims of U.S. Patent No. 9,434,723.
- Patent Validity: The patent is valid, enforceable, and infringed upon.
Mylan's Defenses
- Non-infringement: The biosimilar design does not fall within the scope of the patent claims.
- Patent invalidity: The patent is either anticipated or rendered obvious by prior art.
- Patent would induce infringement: Mylan challenges the likelihood that its actions constitute infringement under the "willful infringement" doctrine.
Claims' Technical and Legal Nuances
| Aspect |
Details |
| Patent scope |
The patent claims cover specific manufacturing processes used in infliximab biosimilar development. |
| Infringement analysis |
Focused on whether Mylan’s process infringes patented steps, considering equivalence arguments. |
| Prior art references |
Multiple publications and patents challenged to invalidate the patent. |
Current Litigation Status and Analysis
Status as of Q1 2023
- Pending motions: Summary judgment motions on patent validity and infringement are under review.
- Discovery: Substantially completed with depositions and document productions.
- Potential outcomes:
- If patent upheld and infringement confirmed: Court may issue an injunction against Mylan’s biosimilar launch.
- If patent invalidated: Mylan could gain clearance to market its biosimilar freely.
Strategic Considerations
| Aspect |
Implication |
Business Impact |
| Patent strength |
Valid patent limits biosimilar competition |
Preserves market exclusivity for Janssen |
| Litigation duration |
Lengthy process delays biosimilar entry |
Competitive delay, potential revenue impacts for Mylan |
| Settlement prospects |
Possible license or settlement |
Accelerates biosimilar market entry |
Comparison with Similar Cases
| Case |
Patent Disputed |
Outcome |
Impact |
| Amgen v. Sandoz (2017) |
Erythropoietin biosimilar patent |
Invalidated patents |
Opened biosimilar market; influenced patent strategies. |
| AbbVie v. Zentiva (2018) |
Humira biosimilar patents |
Court upheld patent claims |
Reinforced patent durability for complex biologics. |
| Janssen v. Mylan (2020) |
Infliximab patent |
Ongoing |
Indicates a trend toward robust patent enforcement. |
Deep Dive: Patent Litigation Strategies in Biosimilars
| Approach |
Details |
Legal Basis/Impact |
| Patent Assertion |
Assert patents to block biosimilar approval |
Courts scrutinize patent scope and validity closely |
| Patent Challenge |
File patent invalidity claims via IPR or litigation |
Can invalidate or weaken patents, enabling biosimilars |
| Settlement Agreements |
License or pay royalties |
Often preferred to avoid lengthy court battles |
Regulatory and Policy Landscape
BPCIA Framework
- Allows biosimilar approval via abbreviated pathway.
- Establishes patent dispute resolution procedures, including:
- Notice of commercial marketing: 180 days prior to market entry.
- Patent dance: Sequential disclosures between innovator and biosimilar applicant.
Implications for Janssen and Mylan
- Patent litigation like this can delay biosimilar entry by years.
- Court rulings influence future patent strategies and the scope of biosimilar claims.
Key Takeaways
- Patent disputes remain central barriers in biosimilar development, often resulting in extended litigation.
- The strength and validity of foundational patents determine market competitiveness.
- Courts evaluate patent claims' scope, prior art, and infringement carefully, influencing biosimilar entry timelines.
- Companies can mitigate risks through patent law knowledge, strategic litigation, and alternative settlement pathways.
- Policy developments like the BPCIA shape the legal landscape, emphasizing patent enforcement and dispute resolution.
FAQs
Q1: How does patent validity impact biosimilar development?
Patent validity determines whether a biosimilar manufacturer can legally market a product. If the patent is upheld, it can delay market entry; if invalidated, biosimilar approval proceeds unimpeded.
Q2: What are the typical durations and costs of biosimilar patent litigations?
Litigations often take 2-4 years, incurring millions of dollars in legal expenses. The process includes pleadings, discovery, and trial or settlement.
Q3: How do biosimilar companies challenge patents like Janssen’s?
They can file patent invalidity claims based on prior art, argue non-infringement, or contest patent scope through inter partes review (IPR).
Q4: What role do the BPCIA provisions play in litigation?
The BPCIA facilitates patent dispute resolution, often triggering patent litigation, and governs biosimilar approval pathways.
Q5: Could settlement agreements influence the outcome of this case?
Yes, settlements or license agreements can resolve disputes quickly, but they depend on the negotiating positions of the parties and strategic considerations.
References
- United States District Court for the District of New Jersey. Case No. 2:20-cv-13103.
- U.S. Patent No. 9,434,723, issued July 5, 2016.
- Biosimilar Price Competition and Innovation Act of 2010, Public Law 111–148 (2010).
- Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).
- Food and Drug Administration (FDA). Biosimilar Development & Approval, 2023.
This analysis is intended for business professionals seeking actionable insights into the ongoing litigation, its strategic implications, and the broader biosimilar patent landscape.
